Antibiotic use and risk of non-Hodgkin lymphomas.

18:12 EDT 27th April 2015 | BioPortfolio

Summary of "Antibiotic use and risk of non-Hodgkin lymphomas."

Clinical case-reports have suggested that specific bacterial infections are associated with certain non-Hodgkin lymphoma (NHL) subtypes. Epidemiological case-control studies have been conducted using antibiotics as a proxy for bacterial infections, but with inconclusive results. The aim of this study was, in a cohort design, based on the unique nationwide Danish registers, to investigate the association between use of antibiotics and the risk of NHL subtypes. Based on the Civil Registration System, we established a cohort of the entire adult (≥15y) Danish population. Information on use of antibiotics came from the Danish Drug Prescription Registry and lymphoma diagnosis from the Danish Cancer Registry. Associations were assessed by adjusted rate ratios (RR). In total, 13,602 patients were diagnosed with one of the NHL subtypes during 51.6 million person-years of follow-up (1995-2008). We observed positive associations between use of antibiotics and plasma cell myeloma (PCM) (RR=1.11, 95% confidence intervals (CI)=1.00 to 1.24), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (RR=1.32, 95% CI=1.20 to 1.45), mantle cell lymphoma (MCL) (RR=1.40, 95% CI=1.04-1.88) and anaplastic large T-cell lymphoma (ALCL) (RR=1.83, 95% CI=1.00 to 3.36). Among these, the increased risk of CLL/SLL, MCL and ALCL, respectively, did not vary by years since use, and only the risk of CLL/SLL risk differed by number of prescriptions. While causality could not be established in the present study, an intriguing positive long-term association between antibiotic use and CLL/SLL risk was observed. To what extent these findings indicate a role for bacteria in lymphoma pathogenesis requires further investigation.

Affiliation

Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark. eeh@ssi.dk.

Journal Details

This article was published in the following journal.

Name: International journal of cancer. Journal international du cancer
ISSN: 1097-0215
Pages:

Links

PubMed Articles [13219 Associated PubMed Articles listed on BioPortfolio]

Medical History, Lifestyle, Family History, and Occupational Risk Factors for Peripheral T-Cell Lymphomas: The InterLymph Non-Hodgkin Lymphoma Subtypes Project.

Accounting for 10%-15% of all non-Hodgkin lymphomas in Western populations, peripheral T-cell lymphomas (PTCL) are the most common T-cell lymphoma but little is known about their etiology. Our aim was...

Paracoccidioidomycosis in Patients with Lymphoma and Review of Published Literature.

This paper describes four new cases of lymphomas, two Hodgkin lymphomas and two non-Hodgkin lymphomas in patients with paracoccidioidomycosis. All had mycosis diagnosed before lymphomas with Paracocci...

Primary Non-Hodgkin Lymphoma of the Breast: Ultrasonography, Elastography, Digital Mammography, Contrast-Enhanced Digital Mammography, and Pathology Findings.

Lymphomas constitute approximately 0.15% of malignant mammary neoplasms. Less than 0.5% of all malignant lymphomas involve the breast primarily. Primary non-Hodgkin breast lymphoma is usually right si...

Non-Hodgkin Lymphoma Dominated by Multiple Organ Extranodal Disease Revealed on FDG PET/CT.

The definition of primary extranodal lymphoma is rather controversial and often complicated by the variety of lymphoma types. Here we describe FDG PET/CT findings in 3 pediatric patients with diffuse ...

Modern radiotherapeutic strategies in the management of lymphoma.

ABSTRACT  The history of radiation therapy in the treatment of malignancies is closely linked to its use in Hodgkin lymphoma. It was less than a decade after the first publication on x-rays that rad...

Clinical Trials [2947 Associated Clinical Trials listed on BioPortfolio]

Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies

The purpose of this study is to investigate possible genetic factors that contribute to the development of lymphomas. The databank will be used to determine whether familial lymphomas hav...

A Study of SB-743921 in Non-Hodgkin's Lymphoma

Cytokinetics' CY 2121 Study is an early-phase trial arranged into two phases. The objectives of the first phase of the study are to assess the safety, tolerability and to identify the max...

Rituximab Post Autografting for Relapsed B-Cell Non-Hodgkin's Lymphoma

High dose therapy with auto stem cell transplant increases the event-free survival in diffuse aggressive lymphomas and low grade lymphomas compared with conventional therapy. However, rela...

Positron Emission Tomography Guided Therapy of Aggressive Non-Hodgkin's Lymphomas

The main purpose of the PETAL trial is to determine whether patients with aggressive non-Hodgkin's lymphomas with a persistently positive PET scan after two cycles of chemotherapy benefit ...

A Randomized Study of EPOCH II Versus EPOCH II and Immunotherapy in Lymphomas

This is a randomized study of combination chemotherapy (EPOCH II) versus EPOCH II and immunotherapy with peripheral blood stem cells (PBSC) and IL-2 in patients with relapsed Hodgkin's and...

Medical and Biotech [MESH] Definitions

External or interstitial irradiation to treat lymphomas (e.g., Hodgkin's and non-Hodgkin's lymphomas) and lymph node metastases and also some autoimmune diseases, such as rheumatoid arthritis.

A form of non-Hodgkin lymphoma having a usually diffuse pattern with both small and medium lymphocytes and small cleaved cells. It accounts for about 5% of adult non-Hodgkin lymphomas in the United States and Europe. The majority of mantle-cell lymphomas are associated with a t(11;14) translocation resulting in overexpression of the CYCLIN D1 gene (GENES, BCL-1).

A vesicant and necrotizing irritant destructive to mucous membranes. It was formerly used as a war gas. The hydrochloride is used as an antineoplastic in Hodgkin's disease and lymphomas. It causes severe gastrointestinal and bone marrow damage.

Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.

Two or more distinct types of malignant lymphoid tumors occurring within a single organ or tissue at the same time. It may contain different types of non-Hodgkin lymphoma cells or both Hodgkin and non-Hodgkin lymphoma cells.

Search BioPortfolio:
Loading
Advertisement

Relevant Topic

The top 5 most promising drugs (February 2014)
Latest News Clinical Trials Research Drugs Reports Corporate
THE FIVE MOST PROMISING DRUGS LAUNCHED OR RECEIVING APPROVAL February 2014 Drug Disease Company Gazyva™ Chronic lymphocytic leukemia Biogen Idec/Genentech/ F. Hoffman-La Roche ...

Advertisement